Can you take Aplisol with Rilonacept?
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- Aplisol (tuberculin purified protein derivative)
- rilonacept
Drug interactions
Moderate drug interactions
Moderate:
tuberculin purified protein derivative rilonacept
Applies to: Aplisol (tuberculin purified protein derivative) and rilonacept
If you are currently being treated or have recently been treated with rilonacept, you should let your doctor know before receiving tuberculin purified protein derivative.
Depending on the dose and length of time you have been on rilonacept, you may have a reduced response to the skin test.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
6 potential interactions Applies to: 6 conditions, including High Cholesterol, Liver Disease, Infection, Tuberculosis, Latent, and Renal Dysfunction.
High Cholesterol
Moderate:
rilonacept
Rilonacept has a moderate potential interaction with High Cholesterol.
Patients treated with rilonacept experienced increases in their mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. The mean increases from baseline for total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were 19 mg/dL, 2 mg/dL, 10 mg/dL, and 57 mg/dL respectively after 6 weeks of open-label therapy. Physicians should monitor the lipid profiles of their patients especially those with hyperlipidemias, and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.
Infection
Moderate:
rilonacept
Rilonacept has a moderate potential interaction with Infection.
Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.
Liver Disease
Moderate:
rilonacept
Rilonacept has a moderate potential interaction with Liver Disease.
No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with hepatic impairment. Caution is advised if used on these patients.
Renal Dysfunction
Moderate:
rilonacept
Rilonacept has a moderate potential interaction with Renal Dysfunction.
No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with renal impairment. Caution is advised if used on these patients.
Tuberculosis, Latent
Moderate:
rilonacept
Rilonacept has a moderate potential interaction with Tuberculosis, Latent.
Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.
Vaccination
Major:
rilonacept
Rilonacept has a major potential interaction with Vaccination.
Live vaccines should not be given concurrently with rilonacept. Rilonacept may interfere with normal immune response to new antigens; therefore, vaccinations may not be effective in patients receiving rilonacept. No data are available on the effectiveness of vaccination with inactivated (killed) antigens in patients receiving rilonacept. Because IL-1 blockade may interfere with immune response to infections, it is recommended that prior to initiation of therapy with rilonacept adult and pediatric patients receive all recommended vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine.
Report options
More resources
Aplisol
A total of 306 drugs are known to interact with Aplisol.
- Aplisol is in the drug class in vivo diagnostic biologicals.
- Aplisol is used to treat Diagnosis and Investigation.
rilonacept
A total of 535 drugs are known to interact with rilonacept.
- Rilonacept is in the drug class interleukin inhibitors.
- Rilonacept is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.